We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Smartphone-Enabled, Paper-Based Quantitative Diagnostic Platform Transforms POC Testing

By LabMedica International staff writers
Posted on 08 Oct 2024

Point-of-care diagnostics are crucial for public health, offering rapid, on-site testing that enables prompt diagnosis and treatment. More...

This is especially valuable in remote or underserved regions where access to laboratory resources is limited. By enabling immediate clinical decisions, point-of-care testing can alleviate strain on healthcare systems and enhance patient outcomes. Now, a new study has demonstrated the effectiveness of a smartphone-enabled, paper-based quantitative diagnostic platform, which improves point-of-care diagnostics by delivering enhanced accuracy, real-time data, and broader accessibility for fast and reliable testing.

The study focused on HueDx’s (Pennsylvania, PA, USA) innovative platform, which comprises HueTools and HueLab. HueDx’s HueTools are artificial intelligence (AI) tools that shorten assay development from years to months while its HueLab customizable cartridge and app, create a portable testing solution that eliminates the need for a traditional lab. This research represents a significant breakthrough in colorimetric diagnostic methods, overcoming past challenges in achieving accurate and consistent results in clinical chemistry at the point of care without requiring additional hardware. The incorporation of smartphone technology enhances these capabilities, allowing for the quantification of previously qualitative assays and enabling real-time data collection and analysis. This will expand point-of-care testing to more providers, including at-home testing, delivering quantitative and actionable results.

The study found that the color correction system restored images to near-perfect consistency, independent of original illumination conditions. In precision testing, the coefficient of variation was nearly twice as high without the color correction. Additionally, limits of blank, detection, and quantification were significantly improved using the HueDx pipeline. The research also demonstrated the platform's effectiveness in calibrating and quantifying a paper-based total protein assay, illustrating its potential for use in point-of-care testing across diverse medical settings.

“The HueDx color correction system represents a major leap forward in diagnostic technology, allowing for accurate and reliable testing in real-world settings,” said Dr. Nidhi Menon, Head of R&D, at HueDx, Inc. “We’re dedicated to enhancing health outcomes with innovative solutions, and our work truly reflects that commitment, setting the stage for the future of smartphone-enabled diagnostics.”

Related Links:
HueDx


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.